Login to Your Account



Proteon Snares $38M Round, and $550M Novartis Option

By Catherine Hollingsworth


Friday, March 6, 2009
Proteon Therapeutics Inc. is banking on its lead product to clear a crucial Phase II study, the results of which could seal a $550 million deal with Novartis AG. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription